Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
4 papers
Recent·Most cited
A. Roy, Y. M. Alhammad, P. McDonald…·A. R. Fehr
This study identifies 5 compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding through high-throughput screening, with IC50 values under 100 µM.
L. M. Sherrill, E. E. Joya, A. Walker…·D. V. Ferraris
This study designs and synthesizes inhibitors targeting the SARS-CoV-2 nsp3 macrodomain, identifying compound 15c as a low-micromolar inhibitor with structural and thermal evidence of binding.
M. A. Dasovich, J. Zhuo, A. G. Thomas…·A. Leung
The paper develops a high-throughput assay for screening inhibitors of the SARS-CoV-2 Mac1 macrodomain and identifies dasatinib and dihydralazine as inhibitors with selectivity over human MacroD2.
N. Zhao, k. Trepka, Y.-h. Wang…·R. Aggarwal
This paper evaluates CDCP1 as a target for radioligand therapy in mCRPC, showing its expression in most biopsies and demonstrating antitumor effects with 177Lu-4A06.